ARCHIVES

Taking Profit Out Of ESAs, Insurer Sending Controversial Drugs Directly To Patients.

This article is from The Cancer Letter archive.

Vol. 36 No. 13 | April 9, 2010

Download PDF Visit The Full Archive

Related Articles

PI Defends NCI’s National Lung Screening Trial As “Rigorous” Randomized Trial.

November 3, 2006

Wistar’s Koprowski; Rivera Is Director

April 12, 1991

Shift Of $6.5 Million From Contracts to Pay Core, P01s At Recommended Levels, Increase R01 Payline

June 27, 1980

Women Surgeons: We Need Answers On Tamoxifin Now

May 13, 1994

In Brief: Move To NCI director’s Office gives Greater Visibility To NCI Liaison Office

September 13, 1996

Study Examines Lung Cancer Among Lifelong Nonsmokers

October 31, 2008